about
Identifying and quantifying heterogeneity in high content analysis: application of heterogeneity indices to drug discoveryOptimization of pyrazole-containing 1,2,4-triazolo-[3,4-b]thiadiazines, a new class of STAT3 pathway inhibitorsComplex gel permeation assays for screening combinatorial libraries.RNAi-based screening of the human kinome identifies Akt-cooperating kinases: a new approach to designing efficacious multitargeted kinase inhibitors.Survivin depletion preferentially reduces the survival of activated K-Ras-transformed cells.Identification of Ras-related nuclear protein, targeting protein for xenopus kinesin-like protein 2, and stearoyl-CoA desaturase 1 as promising cancer targets from an RNAi-based screen.Statin-induced mevalonate pathway inhibition attenuates the growth of mesenchymal-like cancer cells that lack functional E-cadherin mediated cell cohesionLarge-scale generation of human iPSC-derived neural stem cells/early neural progenitor cells and their neuronal differentiation.A Perspective on Implementing a Quantitative Systems Pharmacology Platform for Drug Discovery and the Advancement of Personalized Medicine.High expression of orphan nuclear receptor NR4A1 in a subset of ovarian tumors with worse outcome.A metric and workflow for quality control in the analysis of heterogeneity in phenotypic profiles and screensKinome siRNA-phosphoproteomic screen identifies networks regulating AKT signalingComparison of three cell-based drug screening platforms for HSV-1 infection.Role of Rho kinase pathway in chondroitin sulfate proteoglycan-mediated inhibition of neurite outgrowth in PC12 cells.Connecting Neuronal Cell Protective Pathways and Drug Combinations in a Huntington's Disease Model through the Application of Quantitative Systems Pharmacology.High content screen microscopy analysis of A beta 1-42-induced neurite outgrowth reduction in rat primary cortical neurons: neuroprotective effects of alpha 7 neuronal nicotinic acetylcholine receptor ligands.Integrating Analysis of Cellular Heterogeneity in High-Content Dose-Response Studies.Comparison of 32P-postlabeling and high pressure liquid chromatographic analyses for 7,12-dimethylbenz[a]anthracene--DNA adductsKinase drug discovery by affinity selection/mass spectrometry (ASMS): application to DNA damage checkpoint kinase Chk1From bacterial genomes to novel antibacterial agents: discovery, characterization, and antibacterial activity of compounds that bind to HI0065 (YjeE) from Haemophilus influenzaeAdaptation of an in vitro phospholipidosis assay to an automated image analysis systemA Quantitative Systems Pharmacology Approach to Infer Pathways Involved in Complex Disease PhenotypesBiologically Relevant Heterogeneity: Metrics and Practical InsightsApplications of the microphysiology systems database for experimental ADME-Tox and disease models
P50
Q28540918-19AD4D1D-E0F2-4BDB-80EC-7AC2E7183161Q30276422-7C67D9F0-3702-4192-B0F6-1BFAB837AFCCQ30760392-290A3E6F-6040-4C6C-9794-53B058DB1D26Q33225886-35414CA4-40EF-4B2A-B76D-313B8B42FF63Q33269742-596DA442-8795-45FD-B281-313268DE2408Q33283848-449DA1F8-54E0-42B7-B00F-B6A7E9D3FA81Q34760888-0ADD0500-9115-4A05-8936-4032138F31D9Q36125111-9F60A884-473D-4D4C-932C-44594AA0FB73Q37029832-267B1733-BA5E-490C-96D0-A197A87B4D82Q37500390-01249D70-2C47-4DD5-9608-F868653DDB8DQ37545380-54982D96-7E64-47C2-AD8E-368C06E3486AQ38500176-34331469-5F82-4144-9B6D-C7C230607454Q40273624-AA2CFD90-CC15-4409-AB1E-3D4997FCBDC2Q43549162-053ECA27-6C6F-4473-9A6E-28C7D1E70F9DQ47564614-80DAB72F-0AD0-4BE4-B843-8DF36E2A9EE7Q48194135-7A0914C2-45C3-4140-AD81-1E23D122C3DAQ52373616-03B95B06-7CE8-4E1A-8F56-DDFF78913B11Q70383798-3DFF25C7-437A-40F9-A4A2-5875EA0EC779Q80222923-0DE35BED-BB8D-4B84-ACBB-FEE20586738DQ80505626-5C2D099F-FE2B-4C56-A81E-F829DCE4CF11Q82288775-BB0F8170-9563-468A-8645-EAB190E09906Q88599038-081A8165-EC30-42E1-A183-26F443E86991Q89351018-39884B05-00F2-41BE-BCC4-7CE1A09343ABQ90645696-2FAADC01-3EF1-4EEB-800F-926D0A2F44CB
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Mark E Schurdak
@ast
Mark E Schurdak
@en
Mark E Schurdak
@es
Mark E Schurdak
@nl
type
label
Mark E Schurdak
@ast
Mark E Schurdak
@en
Mark E Schurdak
@es
Mark E Schurdak
@nl
prefLabel
Mark E Schurdak
@ast
Mark E Schurdak
@en
Mark E Schurdak
@es
Mark E Schurdak
@nl
P108
P106
P1153
6602820313
P31
P496
0000-0002-1146-3268